Eli Lilly & Co (LLY): Share Repurchases
$4.11B
Year ended 2025-12-31
+39.9%
3-year compound annual growth
+52.4%
5-year compound annual growth
+18.5%
10-year compound annual growth
| Period ended | Share Repurchases | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $4.11B | +64.3% | 2026-02-12, From 2025-01-01 |
| 2024-12-31 | $2.50B | +233.3% | 2026-02-12, From 2024-01-01 |
| 2023-12-31 | $750.00M | -50.0% | 2026-02-12, From 2023-01-01 |
| 2022-12-31 | $1.50B | +20.0% | 2025-02-19, From 2022-01-01 |
| 2021-12-31 | $1.25B | +150.0% | 2024-02-21, From 2021-01-01 |
| 2020-12-31 | $500.00M | -88.6% | 2023-02-22, From 2020-01-01 |
| 2019-12-31 | $4.40B | +6.0% | 2022-02-23, From 2019-01-01 |
| 2018-12-31 | $4.15B | n/m | 2021-02-17, From 2018-01-01 |
| 2017-12-31 | $299.80M | -50.0% | 2020-02-19, From 2017-01-01 |
| 2016-12-31 | $600.10M | -19.9% | 2019-02-19, From 2016-01-01 |
| 2015-12-31 | $749.50M | -6.3% | 2018-02-20, From 2015-01-01 |
| 2014-12-31 | $800.00M | -52.9% | 2017-02-21, From 2014-01-01 |
| 2013-12-31 | $1.70B | +135.5% | 2016-02-19, From 2013-01-01 |
| 2012-12-31 | $721.10M | n/a | 2015-02-19, From 2012-01-01 |
| 2011-12-31 | $0 | n/a | 2014-02-19, From 2011-01-01 |
| 2010-12-31 | $0 | n/a | 2013-02-21, From 2010-01-01 |
Share Repurchases at similar companies
| Company | Year ended | Share Repurchases | Change YoY |
|---|---|---|---|
| Eli Lilly & Co (LLY) | 2025-12-31 | $4.11B | +64.3% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $5.08B | +289.3% |
| Pfizer Inc (PFE) | 2024-12-31 | $0 | n/a |
| AbbVie Inc. (ABBV) | 2025-12-31 | $980.00M | -42.6% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $0 | n/a |
| Johnson & Johnson (JNJ) | 2025-12-28 | $5.95B | +144.8% |
| Abbott Laboratories (ABT) | 2025-12-31 | $893.00M | -31.0% |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $3.44B | +32.1% |
| Viatris Inc (VTRS) | 2025-12-31 | $500.50M | +100.2% |
Compare LLY, MRK, PFE, ABBV side by side · Screen every company in Pharmaceutical Preparations ↗